Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - February 1, 2024 Category: Allergy & Immunology Authors: Sorawit ChittrakarnPisud SiripaitoonSarunyou ChusriSiripen KanchanasuwanBoonsri CharoenmakThanaporn HortiwakulPhaiwon KantikitNarongdet Kositpantawonga Division of Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla Source Type: research
Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford-AstraZeneca)
CONCLUSIONS: Oxford-AstraZeneca COVID-19 vaccine is able to induce inflammatory CCL2 and CCL3 chemokines as well as protective interferon lambda (IL-29).PMID:38290406 | DOI:10.1016/j.imbio.2024.152789 (Source: Immunobiology)
Source: Immunobiology - January 30, 2024 Category: Allergy & Immunology Authors: Zahra Bagheri-Hosseinabadi Ayat Kaeidi Mahdi Rezvani Gholamhossein Taghipour Khaje Sharifi Mitra Abbasifard Source Type: research
Guillain –Barré syndrome post-SARS-CoV-2 vaccine: a systematic review and data analysis on its clinical, laboratory, electrophysiological, and radiological features
ConclusionThis study aimed to conduct a systematic review of reported cases of GBS following COVID-19 vaccines and descriptive statistical analysis of collected data on clinical, laboratory, electrophysiological, and radiological features, to discuss, based on available results, whether the disease has a predilection to a specific vaccine type and to speculate the potential pathogenesis. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - January 29, 2024 Category: Neurology Source Type: research
Antibody Response after a Booster COVID-19 Vaccine Mixing in Vietnam
CONCLUSIONS: We found that the matching two doses of mRNA vaccines are more immunogenic as compared to the DNA vector vaccines. Furthermore, mixing AstraZeneca-Pfizer has higher antibody quantities as compared to matching vaccines, while lower the rate of advert events.PMID:38273758 | DOI:10.24976/Discov.Med.202436180.17 (Source: Discovery Medicine)
Source: Discovery Medicine - January 26, 2024 Category: Research Authors: Tram Hong Tran Hung Van Pham Thien Huu Doan Bach Kim Nguyen Toi Lam Phung Thai Duy Nguyen Source Type: research
Short term Outcomes of COVID-19 Vaccines Among Lactating Mother and Child Dyads in Bangladesh: A Multi-centre, Cross-sectional Study
DiscussionThis large study of lactating woman-child dyads in Bangladesh, who received a diverse range of WHO-approved COVID-19 vaccines, showed no serious short-term adverse effects. (Source: Maternal and Child Health Journal)
Source: Maternal and Child Health Journal - January 22, 2024 Category: Health Management Source Type: research
Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021: analysis of European pharmacovigilance large-scale data
This study aimed to investigate the reporting rates of arthritis and arthralgia following the administration of four vaccines against SARS-CoV-2: Pfizer-BioNTech (Tozinameran), Moderna (CX-024414), AstraZeneca (Chadox1 NCOV-19), and Janssen (AD26.COV2.S) in 2021. We used data from the EudraVigilance database, specifically analyzing spontaneous reports of suspected adverse reactions (ADRs) from the European Union (EU)/European Economic Area (EEA) region. Age-group-specific reporting rates were calculated by dividing the number of arthralgia and arthritis reports per 1,000,000 vaccine doses administered per age group. Report...
Source: Rheumatology International - January 20, 2024 Category: Rheumatology Source Type: research
Single ChAdOx1 nCoV ‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons
ConclusionsPrevious COVID-19 infection is associated with higher levels of SARS-CoV-2 antibodies following ChAdOx1 (AstraZeneca) vaccination. Our finding supports the notion that a single dose of ChAdOx1 nCoV-19 administered post-SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen for previously infected individuals. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - January 19, 2024 Category: Allergy & Immunology Authors: Fawzi Ebrahim,
Asma Alboueishi,
Inas M. Alhudiri,
Salah Al Tabal,
Yosra Lamami,
Samira Al Dwigen,
Sondos Ashleb,
Noha Ejenfawi,
Mohamed B. Milad,
Hayat Rhoumah,
Salah Edin El Meshri,
Adam Elzagheid Tags: ORIGINAL ARTICLE Source Type: research
